52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
← catalyst calendarNCT06689085 · readout ≤ 590 d
Sponsored by Halozyme Therapeutics (industry) · HALO — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
100estimated
Sites
20
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-07 | actual | When the study began enrolling |
| Primary completion | Mar 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hypogonadism, Male
Intervention
- Combination product: Testosterone enanthate — also filed as XYOSTED Injection
Primary outcome
what the primary-completion date above is the date OFIncrease in testosterone, as evaluated using PK parameters
measured From Enrollment through End of Study Assessments at Week 53
Permalink · HALO's whole pipeline · Catalyst calendar · Every registered study · What changed